HUTCHMED (China) Limited (HK:0013) has released an update.
HUTCHMED (China) Limited has published promising Phase III trial results of its drug sovleplenib, showing a notable durable response rate for treating primary immune thrombocytopenia (ITP), a bleeding disorder. The findings, featured in The Lancet Haematology, indicate sovleplenib’s potential as an effective treatment with a good safety profile. Following the success of the ESLIM-01 study, China’s NMPA has accepted the drug for a priority review.
For further insights into HK:0013 stock, check out TipRanks’ Stock Analysis page.
